Foscarnet

From WikiMD's WELLNESSPEDIA


Information about Foscarnet[edit]

Foscarnet a simple pyrophosphate molecule which has antiviral activity against many viruses and is used intravenously in therapy of serious cytomegalovirus infections, largely in immunocompromised patients. Foscarnet has been associated with mild-to-moderate serum aminotransferase elevations during intravenous therapy, but not with episodes of clinically apparent liver injury.


Mechanism of action of Foscarnet[edit]

Foscarnet (fos kar' net) is a pyrophosphate (phosphonoformate) that has antiviral activity against several DNA viruses, including cytomegalovirus (CMV) and hepatitis B virus. Foscarnet appears to act by inhibition of the pyrophosphate binding sites of viral DNA polymerases. Foscarnet is poorly absorbed orally and must be given intravenously.

FDA approval information for Foscarnet[edit]

Foscarnet was approved for use in the United States in 1991, but has had limited use.


Current indications include therapy of CMV retinitis and acyclovir-resistant herpes simplex infections in immunocompromised individuals. Foscarnet is available as an intravenous formulation of 24 mg/mL generically and previously under the brand name of Foscavir. The recommended dose in adults is 40 to 60 mg/kg intravenously every 8 to 12 hours for 2 to 4 weeks, which must be carefully monitored and dose adjusted for renal insufficiency. Side effects include headache, dizziness, confusion, fever, fatigue, abdominal pain, bone marrow suppression, renal dysfunction and rash. Uncommon but potentially severe adverse events include renal failure, seizures, hypersensitivity reactions, Stevens Johnson syndrome and rhabdomyolysis. Drugs for HIV Infection, in the Subclass Antiretroviral Agents

Drugs for Hepatitis B

Drugs for Hepatitis C

HCV NS5A Inhibitors

HCV NS5B Inhibitors (Polymerase inhibitors)

HCV Protease Inhibitors

Combination Therapies

Drugs for Herpes Virus

Acyclovir, Cidofovir, Famciclovir, Foscarnet, Ganciclovir, Valacyclovir, Valganciclovir

Drugs for Influenza

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.